Want to see AU:PNV full AI Analyst Report?
PNV Stock Chart & Stats
AU$1.01
AU$0.01(0.49%)
At close: 4:00 PM EST
AU$1.01
AU$0.01(0.49%)
Day’s Range― - ―
52-Week RangeAU$0.87 - AU$1.67
Previous CloseN/A
Volume733.50K
Average Volume (3M)1.48M
Market Cap
AU$670.12M
Enterprise ValueAU$847.73
Total Cash (Recent Filing)AU$29.26M
Total Debt (Recent Filing)AU$31.74M
Price to Earnings (P/E)67.6
Beta1.81
Next Earnings
Aug 21, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding690,843,000
10 Day Avg. Volume1,478,953
30 Day Avg. Volume1,476,427
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)9.95
Price to Sales (P/S)6.51
P/FCF Ratio-76.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.56Price Target Upside54.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)AU$187.90M
Bulls Say, Bears Say
Bulls Say
Revenue & U.S. Market PenetrationSustained double‑digit group and U.S. revenue growth with rapid account expansion and a >80‑rep U.S. commercial team points to structural demand for consumable NovoSorb products. A broadening hospital base and recurring procedure‑linked sales support durable top‑line scale and predictable replacement cycles.
High Gross Margins & Improving EBITDAVery high gross margins reflect a low COGS, proprietary polymer platform and pricing power in hospital channels. Coupled with improving adjusted EBITDA, this suggests durable operating leverage: as volume scales (new capacity) fixed costs dilute, supporting sustainable profit expansion over the medium term.
Manufacturing Scale & Regulatory ProgressA validated facility with ~5x capacity materially increases supply flexibility and lowers unit costs, enabling multi‑SKU scale. Simultaneous PMA progress and BARDA partnership materially de‑risks U.S. regulatory pathway, improving long‑term access to hospital tenders and federal accounts.
Bears Say
Weak Cash Conversion And Free Cash FlowDespite revenue and EBITDA gains, poor cash conversion and falling FCF indicate working capital and cash generation issues. Ongoing CapEx for new capacity and inventory build for outpatient could strain liquidity and limit capacity to fund growth or absorb shocks until conversion normalises.
Outpatient Reimbursement UncertaintyExpansion into the outpatient market depends on reimbursement clarity and likely an RCT for CMS coverage. This creates a structural timing and adoption risk: material addressable market upside remains contingent on trial outcomes and slow payer processes, delaying sustained revenue diversification.
Concentrated, Lumpy Case Volumes & Market ComplexityDependence on episodic burn cases and regionally complex tender markets leads to volatile procedure volumes and uneven revenue cadence. This structural concentration complicates forecasting, resource utilisation and margin planning, and slows steady, predictable scale across geographies.
Polynovo News
PNV FAQ
What was Polynovo Limited’s price range in the past 12 months?
Polynovo Limited lowest share price was AU$0.86 and its highest was AU$1.67 in the past 12 months.
What is Polynovo Limited’s market cap?
Polynovo Limited’s market cap is AU$670.12M.
When is Polynovo Limited’s upcoming earnings report date?
Polynovo Limited’s upcoming earnings report date is Aug 21, 2026 which is in 30 days.
How were Polynovo Limited’s earnings last quarter?
Polynovo Limited released its earnings results on Feb 20, 2026. The company reported AU$0 earnings per share for the quarter, missing the consensus estimate of AU$0.006 by -AU$0.006.
Is Polynovo Limited overvalued?
According to Wall Street analysts Polynovo Limited’s price is currently Undervalued.
Does Polynovo Limited pay dividends?
Polynovo Limited does not currently pay dividends.
What is Polynovo Limited’s EPS estimate?
Polynovo Limited’s EPS estimate is <0.01.
How many shares outstanding does Polynovo Limited have?
Polynovo Limited has 690,843,000 shares outstanding.
What happened to Polynovo Limited’s price movement after its last earnings report?
Polynovo Limited reported an EPS of AU$0 in its last earnings report, missing expectations of AU$0.006. Following the earnings report the stock price went down -8.458%.
Which hedge fund is a major shareholder of Polynovo Limited?
Currently, no hedge funds are holding shares in AU:PNV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Polynovo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.56 (54.46% Upside)
AU$1.56 (54.46% Upside)
Blogger Sentiment
Bullish
AU:PNV Sentiment 96%
Sector Average 66%
Sector Average 66%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.90%
Trailing 12-Months
Company Description
Polynovo Limited
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
PNV Stock 12 Month Forecast
Average Price Target
AU$1.56
▲(54.46% Upside)
Technical Analysis
Nova Eye Medical
―
Cochlear
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―